- Home
- IMMX vs COEP Comparison
IMMX vs COEP Comparison
Compare IMMX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- COEP
- Stock Information
- Founded
- IMMX 2014
- COEP 2017
- Country
- IMMX United States
- COEP United States
- Employees
- IMMX N/A
- COEP N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMX Health Care
- COEP Health Care
- Exchange
- IMMX Nasdaq
- COEP Nasdaq
- Market Cap
- IMMX 65.5M
- COEP 62.4M
- IPO Year
- IMMX 2021
- COEP N/A
- Fundamental
- Price
- IMMX $2.00
- COEP $12.50
- Analyst Decision
- IMMX Strong Buy
- COEP
- Analyst Count
- IMMX 1
- COEP 0
- Target Price
- IMMX $8.00
- COEP N/A
- AVG Volume (30 Days)
- IMMX 183.0K
- COEP 38.9K
- Earning Date
- IMMX 11-11-2025
- COEP 11-12-2025
- Dividend Yield
- IMMX N/A
- COEP N/A
- EPS Growth
- IMMX N/A
- COEP N/A
- EPS
- IMMX N/A
- COEP N/A
- Revenue
- IMMX N/A
- COEP $263,555.00
- Revenue This Year
- IMMX N/A
- COEP N/A
- Revenue Next Year
- IMMX N/A
- COEP N/A
- P/E Ratio
- IMMX N/A
- COEP N/A
- Revenue Growth
- IMMX N/A
- COEP N/A
- 52 Week Low
- IMMX $1.26
- COEP $2.31
- 52 Week High
- IMMX $3.20
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- IMMX 48.92
- COEP 50.49
- Support Level
- IMMX N/A
- COEP $12.09
- Resistance Level
- IMMX $2.34
- COEP $13.25
- Average True Range (ATR)
- IMMX 0.15
- COEP 0.73
- MACD
- IMMX -0.08
- COEP -0.13
- Stochastic Oscillator
- IMMX 85.11
- COEP 37.06
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.